Indicated for the treatment of critical limb ischemia (CLI), the product is the first allogeneic cell therapy to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. The company has partnered with Mumbai based pharma company Cipla for the marketing and distribution of the product. BioSpectrum interacted with B N Manohar, Managing Director & Chief Executive Officer, Stempeutics Research, Bengaluru to find out more about this innovative product.
What are the key highlights of Stempeucel?
The key feature of Stempeucel is that it is an on-demand, cryo-preserved, allogeneic regenerative medicine targeting unmet needs. It is physician prescribed and the drug is administered through intramuscular injections around the calf muscle region and around the site of ulcers for CLI treatment. There is a unique patented stem cell pooling technology involved. We have 57 filed patents for this product, 18 international patents granted for Stempeucel pooling technology, including United States, France, UK, Germany, Italy, China, Japan, Australia, New Zealand, Singapore, South Africa and Philippines. It is the first stem cell product with pooling technology to be classified as an Advanced Therapy Medicinal Product (ATMP) and granted Orphan Drug Designation by the European Medicines Agency (EMA) in 2015. Few other indications where this product is being explored includes an ongoing Phase 3 clinical trial for osteoarthritis and diabetic foot ulcer, ongoing Phase 1/2 study for perianal fistula due to Chron’s Disease indication; and we are starting Phase 2 COVID-19 acute respiratory distress syndrome (ARDS) study with the government support.
Please share more details about the CLI treatment procedure.
This story is from the November 2020 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the November 2020 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.
Parse Biosciences announces expansion of Evercode BCR product line
Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.
Gene mutation likely cause for developing autism in early childhood: RGCB study
Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.
RSSDI study lays focus on Yoga and Diabetes Prevention
Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.
